

Innovation towards improved infertility treatments

We identified a drug that activate eggs in infertile women


Market drivers

- Premature ovarian failure
- Aging population
- Increased awareness
- Reimbursement and insurances
- Strong reproductive instinct

Assets

- Growing market
- Strong scientific team
- Fertility consultants
- Experienced Business developers

In house, completed



Ex vivo proof of concept

Outsourced 2020-21



Drug formulation

Clinical trial 2022-2023



FDA approval

Technology Description

Our invention is based in specific data sets that analysed global expression of genes during the earliest stages in egg maturation. We identified a novel potential target and are currently developing a new formulation to enhance activation of dormant eggs in the ovary. The target identified is highly present in the early egg cells and through proof of concept *in vitro* and *ex vivo* studies, we showed that pharmacological treatment could promote activation of the earliest egg cells in aged mice and POI patients, respectively.

We are working towards maturing the technology in a spin-out company.

Intellectual Property Rights

Patent applications: PCT/EP2018/064359 (June 2018) and PCT/EP2018/086239 (December 2018).

Current State

In vitro and *ex vivo* proof-of-concept has been established. The project is, at this stage, funded by soft funding.

In vivo confirmation, CMC and toxicity studies initiated. Phase I/IIa clinical trial is expected in 2022/2023.

Team

Management



Associate Professor
Karin Lykke-Hartmann
Scientific lead



Per Horn, PhD
Business strategy



Postdoc Mahboobeh
Amoushahi,
Reproductive models



Technician Anders Heuck
Single cell techniques



Professor MD Erik Ernst
Fertility treatment

Business opportunity and Call to action

The global fertilization market is projected to reach \$ 27 Billion by 2022 (Grand View Research, Inc)

We are looking to develop collaborations and partnerships for registration studies with companies that has experience in fertility treatment.

Contact information

Morten Holmager
Business Development Manager
Mobile: +45 9350 8718
E-mail: holmager@au.dk

